Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.

Kara-Louise Royle Amy Beth CoulsonKarthik RamasamyDavid A CairnsAnna HockadaySergio QuezadaMark DraysonMartin KaiserRoger OwenHolger W AunerGordon CookDavid MeadsCatherine OlivierLorna BarnardRhiannon LambkinAndrea PatersonBryony DawkinsMike ChapmanGuy PrattRakesh PopatGraham JacksonCeri BygraveJonathan SiveRuth de TuteAndrew ChantryChristopher ParrishMark CookSamir AsherKwee Yong

Published in: BMJ open (2022)

ISCRTN46841867.

Keyphrases

phase ii
newly diagnosed
multiple myeloma
clinical trial
stem cells
open label
study protocol
phase iii
cell therapy
placebo controlled
double blind
bone marrow
randomized controlled trial
contrast enhanced
cross sectional
computed tomography
platelet rich plasma
magnetic resonance
replacement therapy